Cancer Treatment Reviews
Volume 26, Issue 2 , Pages 81-89 , April 2000

Adjuvant interferon-alpha in malignant melanoma: current status

  • B.W. Hancock

      Affiliations

    • Weston Park Hospital, Sheffield
    • ,
  • S. Harris

      Affiliations

    • Weston Park Hospital, Sheffield
    • ,
  • K. Wheatley

      Affiliations

    • Clinical Trials Unit, University of Birmingham
    • ,
  • M. Gore

      Affiliations

    • Royal Marsden Hospital, London

References 

  1. Meyskens FL, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, et al. Randomised trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Nat Cancer Inst. 1995;87:1710–1713
  2. Creagan ET, Ahmann DL, Green SJ, Long HJ, Rubin J, Schutt AJ, et al. Phase II study of recombinant leukocyte A interferon (r-IFN A) in disseminated malignant melanoma. Cancer. 1984;54:2844–2849
  3. Creagan ET, Ahmann DL, Green SJ, Long HJ, Frytak S, O’Fallon JR, et al. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol. 1984;2:1002–1005
  4. Creagan ET, Ahmann DL, Frytak S, Long HJ, Chang MN, Itri LM. Three consecutive phase II-studies of recombinant interferon alpha-2a in advanced malignant melanoma. Cancer. 1987;59:638–646
  5. Legha SS, Papadopoulos NE, Plager C, Ring S, Chawla SP, Evans LM, et al. Clinical evaluation of recombinant interferon alpha-2a (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol. 1987;5:1240–1246
  6. Hersey P, Hasic E, MacDonald M, Edwards A, Spurling A, Coates AS, et al. Effects of recombinant leucocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. Br J Cancer. 1985;51:815–826
  7. Neefe JR, Legha SS, Markowitz A, Salmon S, Meyskens F, Groopman J, et al. Phase II study of recombinant alpha-interferon in malignant melanoma. Am J Clin Oncol. 1990;13:472–476
  8. Dorval T, Palangie T, Jouve M, Garcia-Giralt E, Israel L, Falcoff E, et al. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma. Cancer. 1986;58:215–218
  9. Mughal JE, Robinson WA, Thomas MR, Spiegel RJ. Role of recombinant interferon-alpha-2 in treatment of advanced malignant melanoma. Proc Am Soc Clin Oncol. 1988;7:250
  10. Mickiewicz E, Estevez R, Rao F, Breier S, Balbiani L, Cabalar E, et al. Interferon-alpha-2b (rIFN-alpha-2b) alone or in combination with DTIC in metastatic melanoma (MM). Compiled Data. Proc Am Soc Clin Oncol. 1990;9:281
  11. Kirkwood JM, Ernstoff MS, Davis CA, Reiss M, Ferraresi R, Rudnick SA. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med. 1985;103:32–36
  12. Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegel RJ. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology. 1986;172:275–282
  13. Elsasser-Beile U, Drees N, Neumann HA, Schopf E. Phase II trial of recombinant leukocyte A interferon in advanced malignant melanoma. J Cancer Res Clin Oncol. 1987;113:273–278
  14. Steiner A, Wolf C, Pehamberger H. Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol. 1987;113:459–465
  15. Coates A, Rallings M, Hersey P, Swanson C. Phase II study of recombinant alpha 2-interferon in advanced malignant melanoma. J Interferon Res. 1986;6:1–4
  16. Sheridan E, Hancock BW. Systemic treatment of metastatic malignant melanoma. In:  Kirkham N,  Cotton DWK,  Lallemand RC,  White JE,  Rosin RD editor. Diagnosis and Management of Melanoma in Clinical Practice.. London: Springer-Verlag; 1992;p. 135–156
  17. Legha SS. The role of interferon alfa in the treatment of metastatic melanoma. Sem Oncol. 1997;24:24–31
  18. de Takats PG, Williams MV, Hawkins R. Adjuvant therapy for melanoma: how should we respond to high-dose interferon?. Cancer. 1998;77:1287–1293
  19. Cascinelli N, Bufalino R, Morabito A, MacKie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet. 1994;343:913–914
  20. Cascinelli N. Evaluation of efficacy of adjuvant rIFNα 2 α in melanoma patients with regional node metastases. Proc Am Soc Clin Oncol. 1995;14:410
  21. Cascinelli, N. Data presented at 3rd International Conference on Adjuvant Therapy of Malignant Melanoma. London, 1999
  22. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Co-operative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7–17
  23. Kirkwood JM, Ibrahim J, Sondak V, Ernstoff M, Flaherty L, Smith T, et al. Preliminary analysis of the E1690/S9111/C9190 Intergroup postoperative adjuvant trial of high- and low-dose IFNα2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma. Proc Am Soc Clin Oncol. 1999;18:537a
  24. Grob JJ, Dreno B, de la Salmonière P, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1–5 mm without clinically detectable node metastases. Lancet. 1998;351:1905–1910
  25. Pehamberger H, Sayer HP, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol. 1998;16:1425–1429
  26. Creagan ET, Dalton RJ, Ahmann DL, Jung Sin-Ho, Morton RF, Langdon RM, et al. Randomised, surgical adjuvant trial of recombinant interferon-alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995;13:2776–2783
  27. Kleeberg UR, Bröcker EB, Lejeune F, Chartier C, Egger C, Marsden J, et al. Adjuvant trial in melanoma patients comparing rIFN-α to rIFN-γ to Iscador to a control group after curative resection of high risk primary (>3 mm) or regional lymphnode metastasis (EORTC 18871). The European Journal of Cancer. 1999;35, Supplement 4:S82
  28. Personal communication Cornbleet.
  29. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Co-operative Oncology Group study. J Clin Oncol. 1996;14:2666–2673
  30. Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant interferon-alfa 2b in high risk melanoma based on projections from Eastern Co-operative Oncology Group 1684. J Clin Oncol. 1997;15:2351–2358
  31. Terry WD. Immunotherapy of malignant melanoma. N Engl J Med. 1980;303:1174–1175
  32. Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rumke P. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC PROTOCOL 18781). Eur J Cancer. 1993;29A:1237–1242
  33. Paterson AH, Willans D, Jerry LM, Hanson J, McPherson TA. Adjuvant BCG immunotherapy of malignant melanoma. Can Med Assoc J. 1984;131:744–748
  34. Fisher RJ, Terry WD, Hodes RJ, Rosenberg SA, Makuch R, Gordon HG, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma: preliminary report of the National Cancer Institute randomised clinical trial. Surg Clin North Am. 1981;61:1267–1277
  35. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, et al. A randomised trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982;307:913–916
  36. Balch CM, Smalley RV, Bartolucci AA, Burns D, Presant C, Durant JR. A randomised prospective clinical trial of adjuvant C.parvum immunotherapy in 260 patients with clinically localised melanoma (stage I). Cancer. 1982;49:1079–1084
  37. Bukowski RM, Deodhar S, Hewlett JS, Greenstreet R. Randomised controlled trial of transfer factor in stage II malignant melanoma. Cancer. 1983;51:269–272
  38. Quirt IC, Shelley WE, Pater JL, Bodurtha AJ, McCulloch PB, McPherson TA, et al. Improved survival in patients with poor prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the national cancer institute of Canada clinical trials group. J Clin Oncol. 1991;9:729–735
  39. Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol. 1991;9:736–740
  40. Chan D, Morton DL. Active Immunotherapy with allogeneic tumour cell vaccines: Present status. Seminars in Oncology. 1998;25:611–622
  41. Meisenberg BR, Ross M, Vredenburgh JJ, Jones R, Shpall EJ, Seigler HF, et al. Randomised trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high risk, multinode positive malignant melanoma. J Natl Cancer Inst. 1993;85:1080–1085
  42. Livingstone PO, Wong GYC, Adluri S. Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994;12:1036–1044
  43. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peter L, Ang KK. Cutaneous melanoma. In:  De Vita VTHellman S,  Rosenberg SA editor. Cancer: Principles and Practice of Oncology.. Philadelphia: Lippincott-Raven Publishers; 1997;p. 1947–1994
  44. Personal communication, Gore, M.
  45. Selby P, Gillis C, Haward R. Benefits from specialised cancer care. Lancet. 1996;348:313–318

☆ The authors would like to acknowledge the support of The United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Melanoma Group.

PII: S0305-7372(99)90163-9

doi: 10.1053/ctrv.1999.0163

Cancer Treatment Reviews
Volume 26, Issue 2 , Pages 81-89 , April 2000

Article Tools